2.54 -0.13 (-4.87%) | 07-15 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 3.22 ![]() |
1-year : | 3.72 ![]() |
Resists | First : | 2.76 ![]() |
Second : | 3.19 ![]() |
Pivot price | 2.5 ![]() |
|||
Supports | First : | 2.06 ![]() |
Second : | 1.72 ![]() |
MAs | MA(5) : | 2.59 ![]() |
MA(20) : | 2.45 ![]() |
MA(100) : | 2 ![]() |
MA(250) : | 6.93 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 54.1 ![]() |
D(3) : | 56.8 ![]() |
RSI | RSI(14): 52.8 ![]() |
|||
52-week | High : | 17.75 | Low : | 1.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EVAX ] has closed below upper band by 42.0%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.8 - 2.81 | 2.81 - 2.82 |
Low: | 2.52 - 2.53 | 2.53 - 2.54 |
Close: | 2.65 - 2.67 | 2.67 - 2.68 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Fri, 23 May 2025
Evaxion A/S to Announce Q1 2025 Financial Results and Business Update - TipRanks
Mon, 28 Apr 2025
AI-Powered Cancer Vaccine Shows Breakthrough 80% Success Rate in Advanced Melanoma Trial - Stock Titan
Tue, 25 Mar 2025
Groundbreaking AI Cancer Vaccine Shows Promise: Phase 2 Data Reveals Critical Insights - Stock Titan
Tue, 25 Feb 2025
Evaxion's Cancer Vaccine Shows 69% Response Rate, Trial Extended - Stock Titan
Mon, 30 Dec 2024
Evaxion Biotech Announces 1:5 ADS Ratio Change, Effective January 2025 - Stock Titan
Mon, 09 Dec 2024
Evaxion Biotech Unveils Ambitious 2025 Roadmap: AI-Powered Vaccines, $10M Deal Potential, Clinical Milestones - Stock Titan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 6 (M) |
Shares Float | 155 (M) |
Held by Insiders | 23 (%) |
Held by Institutions | 7 (%) |
Shares Short | 50 (K) |
Shares Short P.Month | 12 (K) |
EPS | -12 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.87 |
Profit Margin | 0 % |
Operating Margin | -431.4 % |
Return on Assets (ttm) | -37.1 % |
Return on Equity (ttm) | -206.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0.52 |
Sales Per Share | 0.52 |
EBITDA (p.s.) | -2.19 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.22 |
PEG Ratio | 0 |
Price to Book value | 1.35 |
Price to Sales | 4.87 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |